Description: Selecta Biosciences, Inc., a clinical-stage biotechnology company, develops targeted therapies that use immunomodulators encapsulated in nanoparticles to induce antigen-specific immune responses to prevent and treat disease. The company focus is on developing and commercializing differentiated therapies that are designed to modulate the immune system to effectively and safely treat rare diseases by mitigating the formation of anti-drug antibodies in response to life-sustaining biologic drugs. Its lead product candidate is SEL-212 for the treatment of refractory and chronic tophaceous gout. The company serves customers in the United States and internationally. Selecta Biosciences, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts.
Home Page: selectabio.com
SELB Technical Analysis
65 Grove Street
Watertown,
MA
02472
United States
Phone:
617 923 1400
Officers
| Name | Title |
|---|---|
| Dr. Carsten Brunn Ph.D. | CEO, Pres & Director |
| Ms. Ann K. Donohue CPA | VP of Fin. & Controller |
| Dr. Lloyd Johnston Ph.D. | Chief Operating Officer |
| Dr. Takashi Kei Kishimoto Ph.D. | Chief Scientific Officer |
| Dr. Peter G. Traber M.D. | Chief Medical Officer |
| Dr. Ulrich H. von Andrian-Werburg M.D., Ph.D. | Co-Founder and Co-Chair of the Scientific Advisory Board |
| Mr. Blaine T. Davis | Chief Financial Officer |
| Mr. Matthew Bartholomae J.D. | Gen. Counsel & Sec. |
| Ms. Kristen Baldwin | Chief People Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 25.4453 |
|---|---|
| Trailing PE: | 5.4444 |
| Price-to-Book MRQ: | 2.3611 |
| Price-to-Sales TTM: | 1.5437 |
| IPO Date: | 2016-06-22 |
| Fiscal Year End: | December |
| Full Time Employees: | 58 |